• Nenad Koruga, Tatjana Pekmezović, Ilijan Tomaš, Anamarija Soldo Koruga, Butković SoldoSilvaS1Department of Neurosurgery, Osijek University Hospital Centre, Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia; 2Institute of Epidemiology, Faculty of Medicine, University of Belgrade, Belgrade, Serb, Zvonimir Užarević, and Krešimir Rotim.
• 1Department of Neurosurgery, Osijek University Hospital Centre, Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia; 2Institute of Epidemiology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia; 3Department of Oncology, Osijek University Hospital Centre, Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia; 4Department of Neurology, Osijek University Hospital Centre, Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia; 5Department of Natural Sciences, Faculty of Education, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia; 6Department of Neurosurgery, Sestre milosrdnice University Hospital Centre, School of Medicine, University of Zagreb, Zagreb, Croatia.
• Acta Clin Croat. 2022 Feb 1; 60 (3): 373-378.

AbstractTreatment of glioblastoma is challenging due to its aggressive and highly invasive nature, and no significant advances in survival have been achieved recently. The aim of our retrospective study was identification of predictive factors and consequent survival outcome in patients who underwent surgical and oncologic treatment of glioblastoma. The study was conducted at the Department of Neurosurgery, Osijek University Hospital Centre. The authors designed a retrospective cohort study in 63 patients who underwent surgical and oncologic treatment between January 1, 2012 and December 31, 2017. Data were collected by reviewing medical records of the patients with histologically proven glioblastoma. Statistical analysis of study results revealed a significant impact of postoperative radiotherapy (p=0.002) and chemotherapy (p=0.016) on progression-free survival and overall survival (p=0.001 and p=0.009, respectively). Postoperative Karnofsky performance scale (p=0.027) was found to be significant in progression-free survival, and so was the interval between surgery and commencement of oncologic therapy (p=0.049). In conclusion, overall survival and prognosis in the treatment of glioblastoma remain poor, although prompt approach in postoperative adjuvant treatments improved progression-free survival.

12 keywords...

hide…